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LONGEVITY: TRANSLATION OF AGING THEORIES INTO ACTION 
ROY MILLER 
ABSTRACT 
 Healthspan describes the length of time an individual lives without 
disability or chronic disease. Characteristic to aging is the risk for the onset of 
both through a progressive accumulation of deficits in normal physiologic 
function. In the past, the declines associated with aging were simply accepted as 
inevitable. Today, longevity research has undergone a meteoric rise in popularity. 
This is due to several landmark studies demonstrating that what was once thought 
of as inevitable has potential to be delayed. This thesis aims to consolidate current 
theories of biochemical processes believed to underlie aging, and explore their 
interconnections. Furthermore, current pharmaceutical and lifestyle interventions 
being studied to promote longevity and target these specific pathways will be 
analyzed for safety and practicality for use in a primary care setting. Through a 
shift from symptom-based care to personalized preventative care, the goal is to 
maximize function into older age and empower individuals to live life to the 







TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………...i 
COPYRIGHT PAGE…………………………    ………………………………...ii 
READER APPROVAL PAGE……………….…………………………………..iii 
DEDICATION ....................................................................................................... iv	
ABSTRACT ........................................................................................................... vi	
TABLE OF CONTENTS ...................................................................................... vii	
LIST OF TABLES ................................................................................................. ix	
LIST OF FIGURES .................................................................................................x	
LIST OF ABBREVIATIONS ................................................................................ xi	
INTRODUCTION ...................................................................................................1	
Lengthening Healthspan, Not Just Lifespan ...............................................1	






Aging Requires Multi-Faceted Diagnostics .................................................9	
	
	 viii 
BIOMOLECULAR THEORIES OF AGING .......................................................13	
The Aging Cofactor: Nicotinamide Adenine dinucleotide .......................15	
Sirtuins ..........................................................................................................18	
mTOR, Insulin Signaling, and the Somatotropic Axis .............................26	
The Human Genome and Longevity ..........................................................28	
INTERCONNECTION OF AGING THEORIES IN AGE-RELATED 
DISEASES .............................................................................................................31	
Cellular Senescence, Chronic Inflammation and Neurodegeneration ....31	
Metabolic Disorders and Cardiovascular Disease ....................................33	
Cancer ...........................................................................................................35	
INTERVENTIONS TO PROMOTE LONGEVITY .............................................37	
Targeting the ‘Dynamic Duo’: NAD and Sirtuins ....................................38	











LIST OF TABLES 
 
 
Table Title Page 















Figure Title Page 
1 Interplay of Physiological Processes in Aging 14 
2 NAD is a critical cofactor for energy metabolism and 
homeostasis 
17 
3 STRING of SIRT 1 protein-protein interactions with 
regard to longevity 
20 
4 SIRT3 maintains mitochondrial energy homeostasis 24 
5 NAD production in different cellular compartments 39 





LIST OF ABBREVIATIONS 
 
AA .......................................................................................................... Amino Acid 
AFAR ...................................................... American Federation for Aging Research 
AMPK ................................................................. 5’AMP- Activated Protein Kinase 
CREB ..................................................... cAMP Response Element-Binding Protein 
CRTC2 .............................................. CREB Regulated Transcription Coactivator 2 
CVD ..................................................................................... Cardiovascular Disease 
CypD ................................................................................................... Cyclophilin D 
DNAm ........................................................................................... DNA methylation 
DSB .................................................................................... Double Stranded Breaks 
ETC ................................................................................... Electron Transport Chain 
FOXO .............................................................. Forkhead Box Transcription Factors 
GCN2 ............................................................... General Control Nonderepressible 2 
GH ................................................................................................. Growth Hormone 
GH/IGF-1 .................................................................................... Somatotropic Axis 
HIF-1ɑ ................................................................. Hypoxia-Inducible Factor 1-alpha 
HIIT ........................................................................ High Intensity Interval Training 
IF ................................................................................................ Intermittent Fasting 
IGF-1 ............................................................................ Insulin-like Growth Factor 1 
IIS ............................................................ Insulin/Insulin-like growth factor System 
LLFS ................................................................................... Long Life Family Study 
MnSOD .............................................................. Manganese Superoxide Dismutase 
	
	 xii 
mPTP ................................................... mitochondrial Permeability Transition Pore 
mTOR .................................................................. mammalian Target of Rapamycin 
NA ...................................................................................................... Nicotinic Acid 
NAD ................................................................. Nicotinamide Adenine Dinucleotide 
NAM .................................................................................................... Nicotinamide 
NAMPT .................................................... Nicotinamide Phosphoribosyltransferase 
NECS .................................................................... New England Centenarian Study 
NF-κB .................. Nuclear Factor kappa-light-chain-enhancer of Activated B cells 
NMN ......................................................................... Nicotinamide Mononucleotide 
NR ......................................................................................... Nicotinamide Riboside 
P53 ................................................................................................ Tumor Protein 53 
PARP ....................................................................... Poly (ADP-ribose) Polymerase 
PGC-1ɑ ........... Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 
RCT ............................................................................ Randomized Controlled Trial 
SASP .................................................. Senescence-Associated Secretory Phenotype 
SC ..................................................................................................... Senescent Cells 
SIRT ................................................................................................................ Sirtuin 
STAC ......................................................................... Sirtuin-Activating Compound 
T2DM ............................................................................... Type II Diabetes Mellitus 
TCA............................................................................................... Citric Acid Cycle 
TNFɑ ........................................................................... Tumor Necrosis Factor alpha 




 The healthcare provider is committed to one thing above all: maintaining 
the longevity and quality of their patients’ lives. With advancements in medical 
practice and technology, humans are now living longer than ever. However, this 
does not necessarily mean we are living better. Symptom mediation seems to have 
taken precedence of treating the underlying cause. Longevity research aims to 
delay onset of chronic disease and disability experienced with age. The ultimate 
goal; to allow individuals to maintain independence and enhance their ability to 
continue living full lives far beyond retirement years.  
 
Lengthening Healthspan, Not Just Lifespan 
There is a critical distinction that must be made when studying longevity, 
and the possibility of promoting longevity in humans. At the surface, the goal of 
longevity research seems to be to get individuals to live for as many years as 
possible. This refers to the extension of ‘lifespan’. However, the word lifespan is 
rooted in the quantity of years and fails to acknowledge the quality of life during 
them. The ultimate goal is to extend ‘healthspan’ which describes the number of 
years lived disease-free with optimal retention of bodily function (15). In 1980, 
scientist Jim Fries attempted to correlate the onset of disease to overall lifespan 
with his ‘Compression of Morbidity Hypothesis’ which argued that centenarians 
are able to live so long by delay of disease and disability onset into later years 
(104).  Follow up studies have provided some support for this theory, but it is 
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clear that this rule does not hold true for all centenarians. While a majority of 
studied centenarians did delay onset of disability into their 90’s, this seemed to 
correlate with an increased functional reserve, not necessarily avoidance of 
disease (104). Thus, it goes to show that while disease and aging are correlated, 
this is far from being the only measure of longevity. The way people reach old 
age is unique and heterogenous. Thus, the true challenge is how to apply 
longevity research findings in an individualized approach, and in a way that is 
practical in a clinical setting such as a primary care office.  
 
Aging is Complex  
Founding director of the New England Centenarian Study Dr. Perls 
described centenarians in his article titled ‘Different Paths to 100’ as having 
multiple routes to longevity including, “the survivor, the delayer, and escaper 
profiles’ (93). This variety provides a clue to the complexity of the genetic, 
environmental, and behavioral factors affecting healthspan which ultimately 
enable someone to reach 100 or above. This conclusion is represented in the 
interplay amongst the numerous physiological processes currently implicated in 
the literature. It is not only important to have one pathway work better than the 
others. Each contributes to over well-being in different ways. 
 Current hallmarks of aging include genomic instability, loss of 
proteostasis, deregulated metabolism or nutrient sensing, mitochondrial 
dysfunction, stem cell exhaustion, and overall altered cellular communication 
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(71). Under each hallmark are biochemical pathways which either aid or detract 
from the body’s ability to maintain functional reserve and delay onset of disease 
and disability. Amongst the most prevalent components are NAD-dependent 
reactions and sirtuins, mammalian target of rapamycin and the somatotropic axis, 
and DNA (24, 19, 18). The overlap amongst these players is astounding and 
provides the true challenge in delaying aging as a certain balance must be kept. 
Some execute functions which promote longevity, and can be thought of as part of 
the ‘protectome’ while others’ chronic stimulation is actually detrimental 
classifying them under the ‘damageome’ for the sake of this thesis. In a final 
addition to this complexity, certain proponents of aging are dynamic and have 
both ‘protectome’ and ‘damageome’ characteristics. It is crucial to demonstrate 
which fall under which so that interventions attempting to improve longevity do 
not also hurt it in the same breath. Through careful deciphering of published 
reviews, randomized controlled trials, and animal studies, this work attempts to 
provide some insight into the application of longevity research in clinical practice. 
Theories will be discussed individually, as well as in conjunction with others, all 
of which will be translated to onset of disease and alteration of bodily function. 
Finally, current interventions being studied will be compared for evidence of 







Specific aims on the following thesis include: 
1. Explore various accepted theories of aging and their interplay; describe the 
environmental, proteomic, genetic and epigenetic factors involved in their 
mechanisms.  
2. Investigate the efficacy and safety of current longevity therapeutics 
including pharmaceutical, lifestyle, and behavioral methods. 
3. Validate longevity therapeutics and discuss the practicality of their 

















The question, “How old are you?” refers to the amount of years passed 
since birth. This is considered to be one’s chronological age. While it is often 
correlated to functionality, maturity, and prevalence of disease, it disregards the 
phenotypic variation observed in older individuals. In order to better understand 
the changes associated with aging, a better measure is required.  
Thus, researchers have shifted their focus to “biological” or 
“physiological” age (46). Biological age is quantified through the use of aging 
biomarkers defined as, “biological parameters of an organism that either alone or 
in some multivariate composite will, in the absence of disease, better predict 
functional capability at some late age, than will chronological age”, rather than 
being based in time (10).  Potential biomarkers for biological age that have been 
identified are, “epi-genetic clocks, telomere length, transcriptomic predictors, 
proteomic predictors, metabolomics-based predictors, and composite biomarker 
predictors” (53). As more interventions claiming to increase healthspan arise, it is 
imperative to identify which of these markers or their combination represent 
biological age most accurately. It should be noted that guidelines to identify these 




1. It must predict the rate of aging. In other words, it would tell exactly 
where a person is in their total life span. It must be a better predictor of 
lifespan than chronological age. 
2. It must monitor a basic process that underlies the aging process, not the 
effects of disease. 
3. It must be able to be tested repeatedly without harming the person. For 
example, a blood test or an imaging test. 
4. It must be something that works in humans and in laboratory animals, 
such as mice. This is so that it can be tested in lab animals before being 
validated in humans. 
While many biomarkers have shown promise, none have met all of the above 
mentioned criteria. Thus, there is a continued need for longitudinal studies to 
improve both the efficacy and practically of these tools (51).  
	
Genetic Biomarkers 
DNA methylation (DNAm) of CpG islands is a process by which gene 
expression and ultimately function is regulated. Specifically, methyl groups being 
present on DNA results in a chromatin configuration which prevents genes from 
being transcribed, inhibiting their expression (26). While it was believed that 
DNAm remained stable throughout life, it has been found that changes in DNAm 
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do occur. Ultimately, varied methylation between individuals is correlated with 
environmental exposures, lifestyle habits, and age. 
  Thus, the “epigenetic clock” was discovered. This model utilizes 
biomarkers of methylation, statistical regression, and adjustment for individual 
variation in CpGs in an attempt to accurately predict biological age. With 
epigenetic changes come alterations in cell differentiation, development, and 
homeostasis (46). Therefore, measuring DNAm differences over time may 
subsequently predict changes in function associated with aging.  
On theme with reduced gene expression is the consideration of telomere 
attrition as a marker for aging. This method follows the idea that telomeres 
shorten during cellular replication and as a result of certain diseases causing, 
“limitation of stem cell function, regeneration, and organ maintenance during 
aging” (49). While measuring telomere length has become as simple as a blood 
draw, this method lacks evidence base in longitudinal mortality studies and has 
yet to be proven as a better predictor than chronological age of function and 
disease risk (76).  
	
Proteomic Biomarkers 
Instead of measuring the regulators of gene expression, other studies have 
attempted to quantify the genes actually expressed. Following the central dogma 
of DNA to RNA to protein, scientists are using transcriptomic and proteomic data 
and correlating them to age-related diseases and phenotypic traits. A recent study 
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of 4,263 individuals aged 18-95 analyzed over 2,925 plasma proteins to develop a 
bioinformatic approach to uncover these changes across the lifespan. It was found 
that throughout life, protein expression changes in waves that are associated with 
disease. This procedure requires only a blood draw, thus increasing its practicality 
as a diagnostic tool. However, many of these “proteomic signatures” also overlap 
with diseases independent of age raising the need for increased specificity (65). 
As more signatures are uncovered, this method’s ability to predict biological age 
will improve, and new targets to slow its progression may come to light.  
 
Metabolomic Biomarkers 
 It should be considered that the genetic methods described, while useful, 
are a few degrees removed from the final product. The genome and epigenome 
give rise to the transcriptome, which provides the blueprint for the proteome, 
whose function produces the metabolome. Each degree of separation is 
accompanied by a multitude of regulatory processes which complicate attempts to 
model aging using the aforementioned techniques. The metabolome being closest 
to the biological phenotype may therefore increase accuracy and be more 
beneficial in efforts to reveal mechanisms of aging. The Wisconsin Registry for 
Alzheimer’s Prevention is a large medical record dataset of individuals with 
parental history of Alzheimer's and dementia. A study done at the University of 
Wisconsin utilized 1,212 longitudinal plasma samples to uncover the top 100 
metabolites most strongly influenced by age. Like the other methods, the 
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quantification of metabolites is as simple as a blood draw. However, the panel of 
metabolites chosen for analysis is key, as different panels have shown to draw 
different conclusions of one’s overall well-being. In addition, metabolites are 
sensitive to acute changes in diet, medication, and state of well-being and are thus 
vulnerable to confounds. All considered, the findings of this study were consistent 
with previous publications, and increased confidence that the metabolome can be 
used to model age, and provides insight to the onset of age-related disease and 
dysfunction (28).  
	
Aging Requires Multi-Faceted Diagnostics 
 Long term studies of centenarians such as the New England Centenarian 
Study (NECS) have demonstrated that those who reach age 100 or above do so in 
many different ways and with a variety of functional outcomes and genetic 
signatures (93). This was further supported by the heterogeneous physical 
findings in the Long Life Family Study (LLFS) of individuals over ninety and 
their offspring (74). While individual categories of biomarkers provide valuable 
insight with regard to specific functional status, it is important to recognize the 
complexity of aging and the need to combine methods in order to better represent 







Table 1 summarizes the findings of a comprehensive review done by Jylhava, and 
demonstrates the specificity of each biomarker to different aging outcomes. While 
the epigenetic clock and telomere length are by far the most studied, alternative 
methods may still hold untapped potential. As such, it is suggested that a 
combination of these methods will likely be utilized as standard in future 
estimations of biological age.  
 
Table 1: Biomarkers of Aging and their Predictive Power (53).  
 
Phenotypes of Healthy Aging  
The search for biomarkers which accurately represent an individual's age 
and function is still ongoing. Thus, alternative methods to elucidate functionality 
and prevalence of diseases associated with aging are still proven to be a valuable 
asset. The LLFS reviewed health records of 426 families across two generations 
with at least one member being over the age of 90. Through this study, five 
‘healthy aging phenotypes’ were developed as measures of functional reserve: 
“immediate and delayed recall was used to develop the healthy memory 
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phenotype, grip strength was used to develop the healthy strength phenotype, 
forced expiratory volume in 1 s was used to develop the healthy pulmonary 
phenotype, systolic blood pressure was used to develop the healthy blood pressure 
phenotype, and the following eight markers were used to develop the healthy 
metabolic phenotype: body mass index, waist circumference, and fasting levels of 
glucose, insulin, triglycerides, high-density lipoprotein cholesterol, interleukin-6, 
and high-sensitivity C-reactive protein” (74). Researchers of the LLFS study 
found that families within the cohort lacked any significant clustering of 
exceptional healthy aging phenotypes. Therefore, while these measures represent 
functional reserve well, it is not apparent that one must be exceptional in all to 
live longer.  
The frailty index, a proportion of accumulated deficits within an 
individual, is another method being utilized to quantify healthy aging. While 
measures of functional reserve are system-specific, the frailty index takes on a 
global view of an individual's state of health. In a study of elderly Canadians, 
Mitnitski and his group found that, “deficits accumulated at 3% per year, and 
show a gamma distribution, typical for systems with redundant components that 
can be used in case of failure of a given subsystem” (80). This represents the 
body’s ability to compensate for deficits as we age in  an attempt to maximize 
function. In addition, significant differences in distribution between healthy and 
morbid groups were also found (80). A meta-analysis of 19 studies published in 
2000 or later revealed that higher frailty index was significantly associated with 
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higher mortality risk (60). Thus, the frailty index represents a powerful indicator 
of an individual's rate of aging and a predictor of all-cause mortality.  
As discussed previously , aging is not the ultimate cause of mortality but 
the onset of disease is. The NECS observed a delay in disease and disability onset 
amongst those living past ninety, which provides support to the ‘Compression of 
Morbidity' hypothesis. While disease genetic variants were still present amongst 
centenarians, a higher frequency of protective  ‘longevity enhancing variants’ 
were found. Specific genetic variants are still being studied, and singular markers 
have yet to be identified as distinguishing between centenarians and normal 
individuals (104). Therefore, prevalence of disease and disability rather than 
relying solely on genetic biomarkers is advised.  
Measuring the rate of change in phenotype, frailty, and disease prevalence 
is proven to be a good measuring of aging. In contrast to biomarkers, which 
require laboratory processing, these parameters are easily quantified through 
physical examination and patient history. In a primary care setting, this 
longitudinal observation is certainly possible and provides invaluable insight to 
the rate at which a person is aging. If found to be excessive, a physician could 
follow up with a composite panel of biomarkers to pinpoint which aging pathways 




BIOMOLECULAR THEORIES OF AGING 
While aging has been investigated in the past and recently sparked new 
interest, the majority of its elusive mechanisms remain unsolved. Traditionally, 
aging was excluded from theories of adaptation or genetic coding. However, 
modern theories fall under two umbrellas: “Programmed Theory” and “Damage 
and Error Theory”. Program Theory suggests that the body functions on a pre-set 
timeline, and, with time,  bodily systems unavoidably decrease in functionality. 
This includes genetic, endocrine, and immunological shifts which lead to protein 
deficiency, metabolic imbalances, and vulnerability to disease. In contrast, the 
Damage and Error Theory identifies damage to bodily systems as environmental 
or a product of overuse (50).  
Today, mechanisms of aging can be categorized under: inflammation, 
accumulation, genomic, metabolic, and homeostatic. These mechanisms overlay 




Figure 1: Interplay of Physiological Processes in Aging. (A) Overview of 
‘nutrient-sensing’ pathways including sirtuins, mTOR, and the somatotropic axis. 
The benefits of dietary modification and caloric restriction are believed to be 
mediated through these proteomic players. (B) Contributors to mitochondrial 
dysfunction, a hallmark of aging. Altered energy metabolism due to imbalance in 
these processes leads to onset of chronic disease associated with age (71).   
	
 
This thesis aims to not only describe them at length, but to provide a 
guideline to their implementation in medical practice. Pathways that enhance 
longevity and slow down aging mechanisms will be described as part of the 
“Protectome” while those which hasten aging processes will be included under 




The Aging Cofactor: Nicotinamide Adenine dinucleotide 
Nicotinamide adenine dinucleotide (NAD) levels dictate cell survival. 
This effect has been referred to as the “Mitochondrial Oasis Effect”. Specifically, 
reduced levels of NAD correlate with reduced survival (117). The consequences 
of decreased NAD have been linked to reduced function of sirtuins (SIRT1-
SIRT7). These proteins have been implicated in multiple aging theories and are 
also believed to  mediate the beneficial effects of exercise and caloric restriction 
described later.  
NAD has noted involvement in numerous physiological processes, and 
over 500 enzymatic reactions. As a result, it has been implicated in energy 
metabolism, mitochondrial biogenesis, and DNA damage and repair (113,97). 
Thus, this cofactor has sparked much interest in the field of longevity and is worth 
examining as a proponent of the “protectome” in longevity.  
	
The Dynamic Role of NAD 
NAD plays a key role in numerous metabolic processes (Figure #). As 
such, any change from homeostatic NAD levels provides insight into the body’s 
metabolic state. Reduced levels of NAD have been associated with multiple 
hallmarks of aging including: mitochondrial apoptosis, reduced ATP production, 
impaired DNA repair, and ultimately cell death (115, 97, 34). These changes 
translate into numerous health issues including obesity, fatty liver disease, and 
metabolic syndrome (89).  In contrast, increases in NAD have been shown to 
improve mitochondrial function under stress, prevent loss of cellular regenerative 
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capacity, and extend lifespan (24). Consequently, elevation of NAD levels in 
humans and animal models has been shown to hinder the onset of 
neurodegeneration, heart dysfunction, metabolic disease, and cancer (34). NAD 
levels are dynamic, and change in response to physiological stimuli and the 
circadian rhythm (24, 54). Upon change in NAD levels, comes change in the 
function of its protein partners and overall function of the cell. Therefore, being 
cognisant of level shifts, and adapting when necessary is a strategy currently 
being pursued in efforts to promote longevity.  
	
	
NAD and Cellular Homeostasis 
  NAD regulates energy metabolism in response to physiologic stimuli and 
stressors through its role in a variety of metabolic pathways (Figure#). Glycolysis 
consumes NAD in the cytoplasm, the citric acid cycle (TCA) consumes NAD in 
the mitochondria, and finally the mitochondrial NADH is utilized by the electron 





Figure 2: NAD is a critical cofactor for energy metabolism and homeostasis. 
Compartmental NAD/NADH levels limit ATP production. Deficiency in NAD 
may lead to disruption of metabolite consumption via glycolysis, TCA, and ETC.  
NAD levels therefore limit the capacity of the cell to produce energy and maintain 
homeostatic conditions (113). Inability of a cell to maintain sufficient pools of 
NAD in both the cytoplasm and the mitochondria ultimately leads to cell death, 
regardless of the availability of glucose (24).  
 NAD changes cellular function through the NAD-dependent sirtuin and 
Poly ADP-ribose Polymerase (PARP) enzymes. Both of these enzymes, whose 
critical functions are discussed in the “Sirtuin” section play critical roles in 
metabolism, genomic stability, and overall healthspan (34). The real dilemma 
arises in the fact that both are ‘NAD-consuming’ proteins. Therefore, while their 
functions promote longevity, they ultimately deplete cytoplasmic, mitochondrial, 
and nuclear NAD levels (55). This emphasizes the need to boost NAD levels in 
older age in order to replenish these pools and maintain cellular health. Methods 
which boost NAD through precursors and enzymatic activation will be discussed 




The protein family of sirtuins (SIRT) is central to a variety of proposed 
aging theories and associated degenerative diseases.  Their importance stems from 
their sensitivity to and dependence on NAD (24).  SIRT proteins are involved in 
‘deacylation reactions’, and act as transcriptional regulators by targeting histones, 
transcription factors, and DNA repair proteins . In total, there are seven 
mammalian sirtuins; all localized to various cellular compartments and involved 
in different pathways (18). SIRT1,6 and 7 are localized to the nucleus and act 
directly on histones to regulate transcription. Beyond this, SIRT 1 also acts on 
transcription factors and DNA repair proteins. SIRT 2 is nuclear as well, but 
translocates to the cytosol upon stress to activate  protective metabolic enzymes. 
SIRTS 3-5 are mitochondrial and are involved in energy metabolism, oxidative 
stress response, and thermogenesis (84).  
Sirtuins, in particular SIRT1 and SIRT3, are nutrient sensing, and respond 
to NAD/NADH imbalances (88,24). Given the prominent role of NAD with 
regard to longevity described earlier, sirtuins are by extension prominent players 
as well. Their dynamic activity places them under the category of both the 
“damageome” and “protectome”, emphasizing the need to carefully monitor the 
safety of sirtuin-modulating therapeutics. While all of the sirtuins seem to play a 
role in cardiac and metabolic health, SIRT 1, 3 and 6 are the most well understood 
and targeted of the seven (55). Thus, the focus will be  on their role in longevity 
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in the following sections. While some protein partners will be described, it is 
important to note that not all will be discussed for the sake of being concise.  
	
SIRT1 
 SIRT 1 is currently the most targeted sirtuin for longevity therapeutics and 
has been associated with the benefits of caloric restriction on health (47). This 
may be due to the discovery that transgenic overexpression of SIRT1 has been 
observed to increase lifespan in yeast, c.elegan, flies in vivo,  as well as human 
cells in vitro (82). As described earlier, SIRT 1 is present in the nucleus and 
functions by regulating gene expression directly through histone modification and 
modulation of transcription factor and DNA repair proteins.  Due to its sensitivity 
to NAD/NADH levels, SIRT 1 acts as one of two ‘fuel sensor’ sirtuins (88). 
STRING, a database which consolidates published protein-protein interaction 
studies, was used to map the most prominent associations to SIRT 1, and the 





Figure 3: STRING of SIRT 1 protein-protein interactions with regard to 
longevity. Key protein partners are displayed as nodes. Utilizing the KEGG and 
Reactome databases, protein partners were filtered by relevant biochemical and 
regulatory pathways. Longevity (Blue), Cellular Senescence (Light Green), 
Cancer (Red), Insulin Signaling (Purple), Circadian Clock (Yellow), Epigenetic 
Regulation (Teal), and Transcriptional Regulation (Dark green). Line thickness 
represents confidence level of interaction based on cited literature.  
  
Amongst the most prominent partners of SIRT1 are tumor suppressor 53 
(p53), forkhead box transcription factors (FOXO), and PPAR. It has also been 
shown that  peroxisome proliferator-activated receptor-gamma coactivator (PGC-
1ɑ), cAMP response element-binding protein/CREB regulated transcription 
coactivator (CREB/CRTC2), and Nuclear Factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) play key roles in the execution of SIRT1 function in 
regard to longevity (81). Stress resistance and lipid catabolism are increased via 
SIRT1 deacetylation of FOXOs and PPAR which are transcription factors present 
in the nucleus, and upregulated under oxidative stress (32).  Deacetylation by 
SIRT1 activates 5’ AMP-activated protein kinase (AMPK) and downregulates 
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CREB/CRTC2 to upregulate glucose and fatty acid uptake under low energy 
conditions in order to maintain energy homeostasis (72). PGC-1ɑ, a central 
regulator of the mitochondria, executes modulation of gene expression in 
response to nutrient imbalances (81). In short, SIRT1 and PGC-1ɑ “coordin[ate] 
metabolic decisions and metabolic status” (85). Given that much of the 
degradation associated with aging is due to excess inflammation, it is also no 
surprise that SIRT1 inhibits NF-κB to limit chronic stimulation of pro-
inflammatory pathways  (116).   
SIRT1 interaction with p53 is a bit complex. It has been proposed that 
SIRT1 signals successful completion of DNA repair by targeting acetylated p53, a 
transcription factor which arrests cell growth following DNA damage. By 
deacetylating p53, and in collaboration with other deacetylases, SIRT 1 abrogates 
apoptosis and cellular senescence and has the potential to return cells to their 
physiological states prior to sustaining damage (110). The complexity arises when 
considering the role of p53 as a tumor suppressor.  Much controversy still lies in 
SIRT 1 has been shown to inhibit p53 in cancerous cells, therefore dampening its 
ability to halt tumor growth. However, studies are now being conducted in which 
SIRT1 antagonism is being used to treat cancer (117). This emphasizes SIRT1 
characteristics of the ‘protectome’ and ‘damageome’, and thus the need to 






 SIRT6, another nuclear sirtuin, has been linked to mitochondrial 
respiration and cellular response to oxidative stress. According to Morris, 
“deficiency of this other nuclear sirtuin in mice leads to low IGF-1, severe 
hypoglycemia, and early death… loss of SIRT6 is accompanied by genome 
instability. This is because during oxidative stress SIRT6 is recruited to sites of 
DNA double-strand breaks, where it stimulates DNA repair through both 
nonhomologous end-joining and homologous recombination” (81). Beyond its 
modification of histones directly in order to control transcription, SIRT6 plays a 
key role in glucose homeostasis via hypoxia- inducible factor 1-alpha (HIF-1ɑ) 
and insulin-like growth factor 1 (IGF-1), oxidative stress  and DNA repair via 
PARP1, and management of inflammation via Tumor Necrosis Factor alpha 
(TNFɑ) and NF-κB (120, 73, 57).  
HIF-1ɑ  is a central regulator of glucose homeostasis and acts as a 
metabolic switch from mitochondrial aerobic respiration to anaerobic glycolysis, a 
process known as the ‘Pasteur Effect’. In addition, it has been deemed a mediator 
of the Warburg Effect, which enables tumor cells to have increased glycolytic 
activity even in normal oxygen-rich conditions. (103).  Numerous studies suggest 
that apart from hypoxia, HIF-1ɑ activity occurs in a growth factor dependent 
manner, particularly in response to IGF-1 (119). SIRT6 deficient mice die 
prematurely due to depleted glucose stores. HIF-1ɑ’s role in the mobilization of 
glucose therefore became of interest as a potential effector of SIRT6 glucose 
	
23 
homeostasis. In Zhong’s study of SIRT6 deficient mice, it was subsequently 
proven that SIRT6 represses HIF-1ɑ expression, and plays important roles in 
managing nutrient stress and limiting cancer growth (120).  
 PARP1 is involved in recognizing single and double stranded DNA breaks 
while moderating their repair (59). SIRT6 becomes involved when considering 
DNA damage due to oxidative stress, and the consequent activation of repair 
mechanisms via PARP1 signaling (73).  In particular, it has been demonstrated 
that SIRT6 deficiency is associated with loss of proper base excision repair,  
vulnerability to DNA damage, and increased aging-associated degenerative 
diseases (83). Similar to SIRT1, SIRT6 also limits NF-κB activity as well as that 
of the proinflammatory cytokine TNFɑ  in response to stress, solidifying its role 
in limiting chronic inflammation and shedding light on its possible involvement in 
cancer (57).  While all currently studied sirtuin-activating compounds (STAC) 
target SIRT1, there is some evidence to suggest that particular free fatty acids 
including myristic, oleic, and linoleic acids may upregulate SIRT6 activity (35). 
Since SIRT6 expression may be modulated, and given its involvement in these 
‘protectome’ pathways, it is critical to keep this protein on the radar when 
attempting to enhance longevity.  
	
SIRT3   
A hallmark of aging is reduced mitochondrial function and energy 
production (71). SIRT3 is located in the mitochondria and is responsible for 
maintaining a state of ‘mitohormesis’, or mitochondrial homeostasis (88). Like 
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SIRT1, SIRT3 is a fuel sensor, and executes its function via NAD-dependent 
deacetylation of a variety of protein partners associated with cellular stress 
response and energy homeostasis (Figure 4).  In addition, its activation is 
associated with the benefits seen under caloric restriction (24). SIRT3 is 
specifically implicated in cardiac function, and has key roles in maintaining 




Figure 4: SIRT3 maintains mitochondrial energy homeostasis. Utilizing 
KEGG/Reactome pathways, a STRING diagram of protein partners was 
developed. SIRT3 modulates key proteins (nodes) involved in longevity (Red), 
energy metabolism (Green), peroxisomal function (Pink), cellular senescence 
(Teal), mitochondrial biogenesis (Purple), and Circadian Rhythm (Yellow). Line 
thickness represents confidence level of interaction supported by cited texts.  
	
 
Protein partners of SIRT3 play key roles in longevity and are 
particularly  cardioprotective, which may explain the high presence of SIRT3 in 
cardiomyocytes (105). These include: cyclophilinD (CypD), mitochondrial 
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permeability transition pore (mPTP), manganese superoxide dismutase (MnSOD), 
FOXO3 and DNA repair protein Ku70 (88). SIRT3 interacts with FOXO3 to 
protect mitochondria from oxidative stress. By clearing defective mitochondria 
(mitophagy), and upregulating mitochondrial biogenesis, the SIRT3-FOXO3 
complex maintains functional reserve and mitochondrial density within various 
tissues (108). The activation of mPTP is associated with reduced mitochondrial 
function, increased cell death, and decline of cardiac function associated with 
aging (25). The SIRT3-CypD complex protects the mitochondria from cellular 
stressors by inhibiting the opening of the mPTP (42). Similarly, SIRT3 activates 
MnSOD to reduce the presence of reactive oxygen species (6). Finally, SIRT3 has 
been shown to promote Ku70 inhibition of Bax, a pro-apoptotic protein in 
cardiomyocytes. By doing so, SIRT3 prevents cardiac cell death and aids in the 
retention of cardiac function under stress and aging (42, 6).  
SIRT3 is associated with the benefits of caloric restriction due to its 
regulatory role in energy homeostasis. SIRT3 coordinates substrate flow into the 
mitochondria and upregulates ETC function under stress. Interestingly, it has been 
shown through genetic knockout models that SIRT3 directly acts on Complex I of 
the ETC, which produces NAD from NADH. Thus, it has been speculated that 
SIRT3 “might act as a rheostat for the ETC ,using NAD generated from complex 
I activity, to, in turn, modulate overall energy homeostasis” (3). Researchers have 
recognized SIRT3 as a ‘protectome’ protein specifically in the context of cardiac 
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health, and its implication in age-related cardiac degeneration will be expanded 
upon.  
	
mTOR, Insulin Signaling, and the Somatotropic Axis  
According to the “mTOR-Centric Ageing Theory”, caloric restriction and 
exercise result in the down-regulation of the protein kinase named mammalian 
target of rapamycin (mTOR) and its downstream effects. mTOR effect on cell 
metabolism, growth, proliferation and survival implicate it in various aging 
pathways as well as cancer (64). Although its role in longevity is considered 
controversial, data in support is widespread and highly consistent across 
independent studies (112). Animal studies also support that pharmaceutical 
inhibition of mTOR by the immunosuppressant Rapamycin (after which it is 
named) increases lifespan in mice (Apelo 2016). Perhaps what allows mTOR to 
be involved in such a variety of aging-related pathologies is its interconnection to 
insulin signaling and the somatotropic axis.  
The mTOR gene actually encodes two distinct complexes, mTORC1 and 
mTORC2. mTORC1 responds to specific amino acids (AA), hormones, as well as 
energetic stress and is responsible for initiating anabolic processes while 
inhibiting catabolic ones to promote cell growth (100). In contrast, mTORC2 
regulates cellular cytoskeleton organization and is involved in insulin signaling 
(112). In mouse models, downregulation of mTORC1 expands lifespan, however 
disruption of mTORC2 seems to be detrimental (64). Therefore, the mTOR 
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pathway, while initially considered to only be part of the “damageome” due to 
mTORC1, seems to also have “protectome” characteristics when considering 
mTORC2 function. Therefore, there is cause for caution when considering this 
pathway as a target for longevity therapeutics, since complete inhibition by 
Rapamycin does not ubiquitously promote longevity (63).  
	
Insulin Signaling, IGF-1 and mTOR 
The insulin/Insulin-like growth factor 1 (IIS) system has been implicated 
in human longevity across a multitude of studies (109, 12). A common theme in 
pro-longevity pathways seems to be a shift from anabolic to catabolic metabolism 
depending on the availability of nutrients to the cell. Given IIS anabolic role, it 
comes as no surprise that reducing its activity may extend lifespan. Excess 
activation of the IIS by insulin or IGF-1 has a multitude of negative effects on 
health including: hypertension, atherosclerosis, and obesity. A study of  192 
centenarian’s offspring has shown lower levels of plasma IGF-1 and increased 
sensitivity to insulin when compared to 82  non-centenarian offspring controls, 
providing further support for the IIS involvement in longevity (111). According to 
LaPlante, mTOR represents the convergence of downstream players activated by 
the IIS (64). Therefore, the rationale follows that by inhibiting mTOR one could 
reduce anabolic effects of the IIS and mimic the beneficial catabolic effects of 





Somatotropic Axis and mTOR 
 Defects in the somatotropic axis have been shown to expand lifespan in a 
variety of studies, particularly of dwarf model systems with growth hormone 
(GH) deficiency (68). GH activates the somatotropic axis during childhood and 
adolescents to promote longitudinal growth, while in adulthood it functions to 
regulate metabolism via downstream activation of IGF-1 (16). A summary of the 
findings in GH-deficient mouse models show reduced circulating IGF-1 and 
insulin as well as increased insulin sensitivity. Overall, median longevity was 
increased by 43% in females and 51% in males (14).  
The effect of growth hormone is important to discuss, as the use of GH 
supplementation is widely promoted as an anti-aging drug. The fad of age-related 
reduction of GH being the cause of fatigue, weakness, and reduced libido in the 
elderly has fueled a pharmaceutical campaign to sell synthetic growth hormone 
without much consideration for its detrimental effects on longevity (94). This 
emphasizes the importance of understanding specific mechanisms of longevity in 
order to protect these patients from claims of false hope and dangerous 
interventions.  
 
The Human Genome and Longevity   
Damage to DNA leading to protein dysfunction has been foundational to 
biomedical research, and aging processes are included. Aging has been found to 
be associated with widespread changes in the genome at both the DNA and 
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chromatin levels. The genome is constantly barraged throughout the lifespan from 
both the environment and internal processes. This results in genetic damage in the 
form of, “point mutations, trans locations, chromosomal gains and losses, 
telomeres shortening, and gene disruption caused by the integration of viruses and 
transposons” (71). Deficits associated with aging come about when DNA damage 
accumulates past a cell’s capacity to repair it, resulting in disruption of proper 
gene expression, cellular senescence, and consequently disease (58).  Although 
these theories provide some explanation to age-associated health decline, it is 
important to recognize that gene therapy in humans is still a new and developing 
field. Therefore, while genetic manipulation may be an option in the distant 
future, it is not a verifiably safe intervention to promote longevity in the present. 
For now, preventative measures can be taken to minimize the amount of DNA 
damage that is accumulated in hopes of promoting longer healthspans.  
	
Telomere Shortening 
  A pillar in aging, “Telomere Shortening” argues that aging is a 
consequence of reduced telomere length with successive cell cycles. Particularly 
in the mitochondria, evidence demonstrates increasing instances of mitochondrial 
heteroplasmy and resultant dysfunction with old age and shortened telomere 
length (121). According to a study utilizing telomerase knockout mice, excessive 
telomere shortening lead to downstream SIRT repression by p53, and modeled 
premature aging.  Furthermore, upregulation of SIRT activity either directly or 
through NAD boosting proved to stabilize telomeres (5). The relationship 
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between healthspan-protective SIRTs and telomere stability hints at the 




The “Relocalization of Chromatin Modifiers Hypothesis” proposes that 
epigenetic changes in DNA in response to double stranded breaks (DSBs) 
accelerates aging, and has been proven in an Inducible Epigenetic Change mouse 
model (55, 58). These epigenetic changes, thought to be caused by chromatin 
remodeling in response to DSBs, are believed to underlie cellular senescence in 
age-related functional decline (58).  Causes of these mutations include air 
pollutants, UV exposure, drugs, diets and more (9).  
The ‘epigenetic clock’ was described earlier as a marker of aging based on 
methylation of CpG islands. This is not only limited to nuclear DNA, but 
mitochondrial DNA as well.  While the association of epigenetic change with 
aging and a variety of disorders has been demonstrated, the exact mechanism of 
degeneration is still yet to be elucidated (9). However, as more is uncovered, 
manipulation of DNA methylation may prove to be a probable intervention to 





INTERCONNECTION OF AGING THEORIES IN AGE-RELATED 
DISEASES 
 So far, we have discussed the bimolecular mechanisms believed to be 
involved in both the delay of aging and its acceleration. These included the 
regulatory role of NAD categorized under the ‘protectome’, the highly dynamic 
sirtuins categorized under both the ‘protectome’ and ‘damageome’, the mTOR/IIS 
signaling network categorized under the ‘damageome’, and the accumulation of 
genomic instability.  The categorization of each translates into their implication in 
a variety of common age-related diseases. As one ages, the ‘protectome’ 
pathways are disrupted while the ‘damageome’ pathways become aberrantly 
activated. To demonstrate this, the basis of five diseases in which age is 
considered a major risk factor will be described including: chronic inflammation, 
metabolic disorders, cardiovascular disease, neurodegeneration, and finally cancer 
(86, 47, 81).  
	
Cellular Senescence, Chronic Inflammation and Neurodegeneration 
 Chronic inflammation is characteristic of a multitude of common aging 
and autoimmune diseases. Cellular senescence, or a state of cell arrest, is believed 
to be a major factor implicated in this phenotype (48). Apart from inhibiting 
cellular proliferation, this state is also associated with a pro-inflammatory 
senescence-associated secretory phenotype (SASP).  Senescence occurs in 
response to stress, but also due to genomic instability, loss of proteostasis, and 
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loss of mitohormesis; all of which were associated with the dysfunction of the 
molecular theories of aging described earlier (98). In particular, SASP is 
dependent upon known protein partners of sirtuins and mTOR including NF-κB, 
p53, AMPK, and IGF-1. Furthermore, SASP is  associated with elevated levels of 
chemokines, cytokines, and growth factors which are deemed as markers of 
‘inflammaging’, or age-related chronic inflammation (61).  To add insult to 
injury, as senescent cells (SC) accumulate, neighboring cells become affected by 
their proinflammatory factors, hence the term ‘zombie cells’ (102). Increased 
quantities of SC cells have been associated with chronic inflammation and 
neurodegenerative disorders including Alzheimer’s and Parkinson’s disease (61, 
38, 22).  
 SIRTs moderate both adaptive and innate immunity in response to T-cells 
(81). In an interview with longevity physiologist Peter Attia, Dr. Sinclair 
explained that  as genomic damage is accumulated throughout life, sirtuins are 
constantly being relocalized in an attempt to repair it. However, there is a point 
when sirtuins are ‘spread too thin’ and can no longer compensate (1). Specifically, 
SIRT1 and SIRT6 inhibit NF-κB transcription to limit the body’s inflammatory 
response (116, 57). Therefore, impaired sirtuin activity allows acute inflammation 
to progress into the chronic pathologic inflammation observed in disorders such 
as osteoarthritis.  
 SCs can also be triggered by oxidative stress observed in dysregulated 
mTOR signaling. mTOR inhibition by rapamycin has been shown to reduce 
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interleukin 1 receptor mediated SASP via transcriptional suppression of NF-κB 
(66). Furthermore,  mTOR activation due to defective growth factor and AA 
signaling leads to loss of  mitohormesis and the production of ROS-induced 
genotoxic stress seen in SCs (90). There is also evidence that sirtuins, particularly 
SIRT1, downregulates mTOR activity in response to stress (45). Considering this 
interplay between the highly implicated SIRT and mTOR, and given mTOR’s role 
as a key component of mitochondrial biogenesis and IGF-1 signaling, it is 
plausible that dysregulation of mTOR may underlie chronic inflammation seen in 
aging.  
	
Metabolic Disorders and Cardiovascular Disease 
Metabolic decline is another proponent of aging currently being studied. 
The founder of the Institute for Aging Research,Dr. Barzilai, argues that “aging is 
arguably the most universal contributor to the etiologies of metabolic decline 
including type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and 
stroke” (14). Studies suggest that throughout our lifespan, metabolism shifts into a 
more anabolic state. This is characterized by  increased adiposity and a state of 
insulin resistance coupled with excessive glucose production known as metabolic 
syndrome. In a meta-analysis of 20 cohort studies including over fifty thousand 
patients, researchers found metabolic syndrome to be associated with higher risk 
of all cause mortality in the elderly (52).  Similarly to chronic inflammation, this 
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impairment of metabolism implicates multiple aging theories. Thus, the 
complexity of why we age is once again emphasized.  
The altered metabolism associated with aging involves the interplay 
between sirtuins, mTOR, and the somatotropic axis (14). As mentioned earlier, 
sirtuins inhibit PPAR to limit its adipogenic effects in response to changes in 
nutrients. Given that PPAR activity helps determine age-related insulin resistance, 
SIRT1 appears to be the link between diet, body fat, and age-related diseases (32). 
In addition, SIRT1 deficient mice lack the ability to regulate mTOR signaling. 
Excessive mTOR activity, and the crosstalk with IIS signaling results in insulin 
resistance and a loss of glucose homeostasis which are both characteristic of the 
aforementioned diseases (81).  
Also believed to have a role in aging is the somatotropic axis (GH/IGF-1). 
There is much debate on whether the decrease in GH/IGF-1 or its increase is best 
for longevity. Dwarf mouse models which lack the GH receptor show significant 
extension of life, and mutations in the IGF-1 receptor gene are more common in 
centenarians than the young (68). Paradoxically, low circulating IGF-1 has also 
been associated with increased risk of CVD and other metabolic-mediated 
diseases. This has led researchers such as Barzilai to conclude that attenuation of 
the GH/IGF-1 axis must be optimized, not necessarily abolished, as it contains 





 Aging is also considered a risk factor for cancer, and involves altered 
signaling of the three sirtuins discussed (SIRT1/3/6) as well as the mTOR 
pathway (81, 14). However, their effect on cancer is not unidirectional, and 
attenuation of their function should therefore be approached cautiously. Each 
protein's role in the cancer pathology can be uncovered by revisiting key protein 
partners and their downstream effects. This includes SIRT1 interplay with the 
tumor suppressor p53,SIRT6 response to DNA double stranded breaks, SIRT3 
regulation of HIF-1ɑ, and mTOR upregulation of mitochondrial respiration (117, 
73, 101,90).  
 SIRT1 is a known inhibitor of the tumor suppressor p53, and is 
upregulated in a variety of cancers (47). However, downregulation of SIRT1 is 
also associated with excessive DNA damage and loss of genomic stability which 
leaves cells vulnerable to mutations and tumorigenesis (117). Therefore, both 
SIRT1 activators and inhibitors are being considered as potential cancer 
therapeutics, yet it seems as though a dynamic regulator of SIRT1 which would 
allow it to function at an optimal level is needed. SIRT6 is a central player in 
regulating DNA repair of double stranded breaks under stress, primarily via 
activation of PARP1 (32, 73). In contrast to SIRT1, SIRT6 acts solely as a tumor 
suppressor by preventing the accumulation of DNA damage caused particularly 
by oxidative stress (73). Since genomic instability is a basis for tumor production, 
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it comes as no surprise that SIRT6 has now become a target of cancer 
therapeutics.  
 Cancer cells mandate a high amount of energy, and require an 
upregulation of anaerobic metabolism to survive in their overcrowded, hypoxic 
environment (4). Involved in this metabolic shift is HIF-1ɑ which is regulated by 
SIRT3 and mTOR signaling. Normally, SIRT3 inhibits HIF-1ɑ stimulation of 
glycolysis in response to oxidative stress. However, SIRT3 deficiency observed in 
human breast cancer allows for unregulated HIF-1ɑ activation even under 
normoxic conditions. This results in upregulation of glycolysis (Warburg Effect) 
as part of a pseudo-hypoxic response which nurtures tumor cell growth and 
proliferation (101). Similarly, mTOR is also upregulated in response to oxidative 
damage. It’s activity, particularly mTORC1, stimulates mitochondrial respiration 
and increases ATP production to fulfill the energy requirements of highly 
proliferative cancer cells (90). Furthermore, it is also associated with HIF-1ɑ 
activation like SIRT3 (66). As such, modulation of mTORC1 activity is also 
considered to be a potential anti-cancer therapeutic. However, not much is known 
about the role of mTORC2, which further complicates the targeting of this 





INTERVENTIONS TO PROMOTE LONGEVITY 
 Humans have been looking for the “fountain of youth” for centuries. 
According to University of Delaware historian Carol Haber, the search began 
between the 15th and 16th centuries with the intention of preserving the elderly’s 
ability to pass on precious knowledge. Then, between the 19th and 20th centuries, 
a shift began to take place (41). The goal then became to not age at all.  
Modern longevity research continues to toe the line between improving 
quality of life into older age and ostracising the aged. As “anti-aging” hype 
continues to snowball, it becomes critical for providers to be aware of current 
research on aging interventions in order to protect a vulnerable geriatric patient 
population. Things such as unregulated supplements, off-label use of 
pharmacologic agents, and hormone replacement being marketed directly to 
consumers without proper safety standards are becoming more and more 
prevalent. However, while some interventions have yet to be proven, others have 
demonstrated promise in the efforts to slow down aging and preserve function.    
This section aims to identify current interventions whose efficacy and 
safety are largely supported by translational research and clinical findings.These 
interventions can be categorized into the following categories: lifestyle habits, 
pharmacologic agents, and orthomolecular medicine.  It is important to note that 
in the case of longevity, it is difficult to conduct comprehensive longitudinal 
studies primarily due to their length and subsequent cost. In addition, medical 
practitioners must be aware of  greed driven predation of the elderly patient 
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population. Dr. Perls, the founding director of the NECS, wrote in an Aging 
Health article of the four major events leaving older patients vulnerable to 
potentially dangerous therapeutics: a growing population of baby boomers 
searching for a fountain of youth, television shows advertising unproven therapies 
with a false backing by celebrities, loopholes in the Dietary Supplement and 
Education Act allowing politicians to market unregulated products directly to 
consumers, and finally underfunding of governmental enforcement agencies (95). 
Therefore, cautionary measures will also be discussed.  
	
Targeting the ‘Dynamic Duo’: NAD and Sirtuins 
As described earlier, NAD and the NAD-dependent sirtuins are central to 
a multitude of physiological functions and aging processes. Thus, many groups 
are now searching for ways to boost their activity. However, sirtuins are involved 
in a multitude of longevity pathways, some under the umbrella of the 
‘protectome’ while others fall under that of the ‘damageome’. A leader in NAD 
boosting and sirtuin activating therapies, Dr. Sinclair, describes sirtuin activity as 
a ‘double-edged sword’, emphasizing the need for rigorous testing for safety and 
dosage (18). Today, there are several NAD precursors and STACs being tested in 
clinical trials, the most promising of which will be described.  
	
Boosting NAD: Niacin, NR, and NMN 
The methods by which we can raise cellular NAD levels are rooted in the 
synthesis, salvage and metabolism of NAD itself. NAD is produced in the 
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cytoplasm, nucleus and mitochondria (55). NAD is synthesized de novo in the cytoplasm 
from dietary tryptophan in a process known as the kynurenine pathway. NAD salvage 
occurs in the cytoplasm as well as the mitochondria and nucleus from recycled 
precursors: nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), 
nicotinamide (NAM), and nicotinic acid (NA) 
(97).The possibility to upregulate mitochondrial and nuclear NAD production is based in 
the fact that these precursors may be transported across plasma membranes for utilization 
(Figure 5).  
Figure 5: NAD production in different cellular compartments. NAD is produced de 
novo in the cytoplasm or via salvage pathways in the cytoplasm, nucleus, and 
mitochondria. Current interventions to promote longevity include addition of precursors 
and subsequent upregulation of salvage pathways (Blue) , direct activation of 
nicotinamide phosphoribosyltransferase (NAMPT), and inhibition of NAD-consuming 
enzymes SARM1, CD38, and PARP1 (55).  
Niacin, used to describe nicotinic acid (NA),is a form of vitamin B3 
initially used to treat artherosclerotic cardiovascular disease due to its ability to 
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increase the amount of high density lipoprotein (37). Niacin being a precursor to 
NAD made it a molecule of interest in the efforts to increase longevity. However, 
while it was proven to raise NAD levels in rodents, there is little data supporting 
its ability to do so in humans (97). Noted side effects of niacin include, “impaired 
glucose tolerance, rise in uric acid, and, more rarely, rises in liver enzymes and 
myopathy” (56). Furthermore, a systematic review of thirteen RCTs of 35,206 
individuals noted no significant difference of all cause mortality between niacin 
and control arms as treatment for reducing cardiovascular events (37).Therefore, 
niacin does not represent a good candidate for the promotion of longevity.  
NR, another proponent of the vitamin B3 family, proves to be a more 
promising precursor to boost NAD. NiagenⓇ is an NR which has been studied in 
several clinical trials to date, and is being brought to market by TRU NIAGEN. A 
2 x 6 week randomized controlled trial (RCT) of NiagenⓇ in healthy middle aged 
adults demonstrated its ability to stimulate NAD levels in the blood without 
adverse effects (75). According to TRU NIAGEN, no known drug interactions are 
expected. This is critical when considering the ever prevalent polypharmacy 
present in the elderly patient population (43). 
NMN is another NAD precursor being used to upregulate NAD production 
in cells. NMN is synthesized during the rate-limiting step of NAD synthesis under 
the function of NAMPT. It is also made from NR via NR kinase activity, 
shedding light on Niagen’s ability to bypass the rate-limiting NAMPT (17). 
According to a review by Yoshino, NMN improves insulin sensitivity, 
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mitochondrial function, neuro cognitive function and endothelial function in mice 
(118). Moreover, neuroprotective compounds P7C3 which activate NAMPT have 
also been found to upregulate NAD production via this salvage pathway which 
provides supporting evidence to NMN’s ability to limit neuronal degeneration 
(18). According to the US National Library of Medicine, there is only one 
ongoing clinical trial of NMN effect on cardiometabolic function, therefore 
physicians should hesitate to recommend the use of this supplement which is 
commercially available. As more studies will be conducted, it is worthwhile to 
keep NMN on the radar of potential longevity interventions.  
	
Sirtuin-Activating Compounds  
 Sirtuins have been shown to mediate the health benefits of caloric 
restriction and are implicated in age-related diseases in a multitude of studies (47, 
82, 15). STACs are pharmacological activators of sirtuins which, like NAD 
precursors, seem to delay aging and prevent the onset of age-related diseases and 
disability (47). The first STAC to be discovered and studied was resveratrol, a 
polyphenol found in red wine and grapes. Due to the high cost on long-term 
clinical studies, clinical trials of this STAC have been limited to disease-specific 
and short term studies. Through these studies, resveratrol has been described to 
have antioxidant, anti-inflammatory,  and anti-neurodegenerative properties 
which are protective against  cardiovascular, metabolic, and cognitive decline 
(15). However, resveratrol also presents a few risks which make it difficult to 
justify its widespread use in clinics. These problems include low absorption and 
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bioavailability, lack of specificity to SIRT1, and disruption of normal drug 
metabolism due to cytochrome P450 inhibition which poses an even greater risk 
to the elderly who commonly take multiple medications at once (39, 30). Early 
synthetic activators such as SRT1720 also had low target specificity and thus have 
not made it into practice (18). The search for a specific and bioavailable 
compound is still ongoing. 
 Currently, a number of synthetic pharmacological activators of SIRT1 are 
being tested in clinical trials. GlaxoSmithKline, a british multinational 
pharmaceutical company, is currently studying three synthetic STACs including 
SRT2104, SRT2379, and SRT3025 in hopes of gaining approval for clinical use 
(27). According to a review by Dr.Dai, only SRT2104 was found to have potential 
longevity promoting effects while SRT2379 and SRT3025 studies have 
subsequently been discontinued (27). RCTs of SRT2104 have shown some 
promise. In psoriasis, an inflammatory disease, SRT2014 was demonstrated to 
reduce inflammation by modulating TNFɑ activity (62). A study of T2DM 
patients showed that while SRT2104 may not have an effect on glucose or insulin 
signaling, it does improve lipid profiles (11). Finally, a pilot study in elderly 
volunteers showed that SRT2104 is tolerable and mimics the benefits associated 
with increased SIRT1 activity (67). However, all of these studies pointed out that 
while there are noted benefits, SRT2104, like the other STACs mentioned, is not 
able to overcome bioavailability and specificity issues. Thus, there is still a need 
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to find a compound which is absorbed well and accurately targets SIRT1 without 
off-target effects.  
 
Senolytics: Fighting ‘Zombie Cells’  
Cellular senescence and the associated SASP phenotype has been 
implicated in various age-related diseases. Therefore, current studies aim to 
selectively eliminate these cells primarily by targeting their pro-survival 
mechanisms which allow them to avoid apoptosis in the first place (44). Agents 
which aim to accomplish this are categorized as Senolytics. “Hit and Run” 
treatment with senolytics such as the Dasatinib/Quercetin cocktails have been 
demonstrated to  reduce p16INK4A and p21C1P1+ expressing cells (SC cells) in both 
idiopathic pulmonary fibrosis and diabetic kidney disease. Noted Improvements 
included increased tolerance to exercise and a reduction in inflammatory markers 
(44, 47). It is important to note that both of these studies were modest in size with 
9 patients being included in the diabetic kidney disease trial and 14 in the IPF 
trial. In addition, neither study observed significant improvements in frailty index 
or self-reported states of well-being. Therefore, there is still a need to find 
senolytics which can promote longevity not only in those suffering from chronic 







 The mTOR pathway has numerous implications in the acceleration of 
aging by promoting cell proliferation, growth, and inflammation. Interestingly, 
mTOR was named after the immunosuppressant, Rapamycin, which used to be 
considered an antifungal agent until its inhibition of T-cell proliferation was 
discovered and connected to the mTORC complexes (7). While both complexes 
fall under the same gene, their varied response to Rapamycin is critical for 
understanding the risk and benefit of utilizing this drug as a longevity 
intervention. Specifically, mTORC1 is inhibited by acute dosing of Rapamycin 
and has been shown to extend lifespan in yeast, flies, and mice (7). Usually, 
mTORC1 allows cancer cells to keep up with high energy demands under hypoxic 
conditions, however Rapamycin treatment has been shown to prevent this survival 
mechanism making it a potential anti-cancer therapy. In addition, inhibition of 
mTORC1 has been shown to be protective against Alzheimer’s, Parkinson’s, and 
Huntington’s in animal models (66). However, chronic administration has been 
shown to inhibit mTORC2 function and results in glucose intolerance and insulin 
resistance (63, 19). 
Rapamycin’s effect is variable across different organisms and lacks 
efficacy. To solve this, combination therapies are now being constructed to better 
target particular pathways. These molecules, called Rapalogs, target specific 
receptors to increase Rapamycin inhibition including: IGF-1R, receptor tyrosine 
kinases, and growth factor inhibitors (66). Currently, the use of Rapamycin in 
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healthy patients has yet to be proven safe, and more work must be done before its 
utilization in clinics.  
 
Metformin 
 Metformin is a pharmaceutical agent which lowers blood glucose, and is 
currently being used robustly to treat T2DM (71). When it was observed that 
diabetics taking metformin had lower mortality than non-diabetic not taking 
metformin,  it came into focus as a potential pro-longevity therapeutic. A meta-
analysis by Dr. Campbell concluded that Metformin users had a reduction in 
instances of CVD and cancer (23). A study of clinical trials also noted reduction 
in these diseases, as well as a reduction in neurodegeneration, inflammation, and 
frailty (96). The ‘geroprotective’ properties of this drug may be attributed to its 
‘fasting mimetic’ properties such as activation of AMPK to reduce excessive 
glucose production, inhibition of methionine metabolism which is linked to 
extended lifespan, and finally improved response to insulin to prevent the 
deleterious effects of T2DM (71). Given the potential benefits of metformin 
beyond just treating diabetes, Barzilai and collaborators from AFAR have set out 
to prove its safety and pharmacodynamic efficacy through TAME; the Targeting 
Aging with Metformin clinical trial (107). If the trial is successful, not only will 
metformin become an approved drug to delay aging, it will change its definition 
all together and classify it as an indication, which will hold vast weight when 
considering public health and insurance stipulations. Overall, metformin seems to 
	
46 
be a promising pharmaceutical which may be utilized in practice beyond just 
diabetes within the next 10 years.  
	
Dietary Modification  
Organisms, under the 24-hour dark/light cycle, have evolved to develop a 
24 hour circadian rhythm. Amongst many other things, it is an internal signal to 
acquire food when it is available, and utilize stored energy when it is not without 
compromising vitality. Thus the question arose; what mechanisms enable the 
retention of function without additional energy intake? Through studies of 
religious groups practicing periodic fasts, animal models, and lower eukaryotes it 
was discovered that fasting not only triggers compensatory mechanisms which 
retain normal function, but promotes longevity (77).  
To understand the benefits of dietary restriction and fasting, one must first 
understand the mechanisms and observed benefits of 'fasting physiology’ as they 
relate to pillars of aging. According to a recent review published in the New 
England Journal of Medicine, “intermittent fasting elicits evolutionarily 
conserved, adaptive cellular responses that are integrated between and within 
organs in a manner that improves glucose regulation, increases stress resistance, 
and suppresses inflammation” (29). These benefits occur in response to changes 
in the nutrients described earlier, NAD, ATP and Acetyl CoA, all of which are 
converted to NADH, AMP , and CoA in the fasted state. Upon this shift in energy 
state, transcription factors implemented in a multitude of longevity pathways are 
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activated. This includes the FOXOs,PGC-1ɑ, AMPK, and SIRTs. In addition to 
the upregulation of these “protectome” pathways, “damageome” pathways such as 
Insulin-IGF-1 and mTOR are downregulated due to a lack of circulating AA, 
glucose  and insulin. This shift from anabolism to catabolism limits the use of 
resources for growth and, “favors maintenance and repair systems, enhancing 
stress resistance, recycling damaged molecules, stimulating mitochondrial 
biogenesis, and promoting cell survival” (29). Thus, researchers have conducted a 
multitude of studies and clinical trials in hopes of uncovering what regimens best 
promote longevity. In the following sections a select number of regimens 
currently believed to be most beneficial to longevity will be described. These 
regimens vary in not only amount of calories consumed, but time of feeding and 
actual food content.  
	
	
Intermittent Fasting: When to Eat and How Much 
Intermittent fasting (IF) describes, “eating patterns in which individuals go 
extended time periods (e.g.16-48hr) with little or no energy intake, with 
intervening periods of normal food intake, on a recurring basis” (77).  According 
to a review on the metabolic effects of IF, there are three methods commonly 
being utilized to impact health. These include alternate day fasting, modified 
fasting, and time restricted feeding (TRF) (92). Alternate day fasting involves 
days without any energy intake coupled with days of free eating. The modified 
regimen is similar except there is a 20-25% energy intake on fasting days; this is 
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the basis of the popular 5:2 diet which restricts energy intake for 2 days and 
allows free eating the other 5. Finally, TRF pertains to free eating within specific 
time frames broken up by longer periods of fasting; this is commonly practiced in 
a 16 hour fast to 8 hour eating frame structure (92).  Each regimen is associated 
with a variety of benefits and levels of practicality which should be considered on 
an individualized basis.  
Alternate day fasting is an example of a method which presents metabolic 
benefits, but is simply not practical. In both rodents and in a limited amount of 
human clinical studies it was demonstrated that this regimen reduces triglyceride 
production post-meals, elevates HDL while lowering LDL, and shows 
improvement in inflammatory biomarkers (92). However, Dr.Heilbronn who 
studies fasting regimens in both obese and non-obese adults points out that many 
complain of increased hunger without relief over time while undergoing this 
regimen (91). Therefore, this method is not very popular and lacks consistent 
patient compliance.  
The modified regimen seems to have come about as a solution to the 
hunger experienced in the alternate day fasting routine. Evidence for this diet's 
effect on metabolism and longevity is, however, limited. A 19 subject randomized 
study found that under the 5:2 regimen, individuals undergo a metabolic switch to 
catabolism represented by a reduction in fasting glucose and body fat, as well as 
an increase in ketone bodies and lean mass relative to whole body weight (20, 70). 
Furthermore, low reports of adverse effects such as hunger indicate that this 
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regimen not only produces the benefits of caloric restriction, but is also less 
difficult to comply with.  
TRF is seemingly the most studied method of intermittent fasting. TRF 
was founded within the concept of circadian rhythms, and exploits the body's 
transcriptional and translational feedback loops rather than nutrient composition 
to modulate metabolism (70).  The circadian clock activates catabolic and 
anabolic pathways depending on fasted and fed state prevalent in ancient species 
who ate during the day and fasted throughout the night. However, in today’s 
society where food is always readily available, the body remains at a steady fed 
state which negates the potential benefits of fasting physiology (70). TRF caloric 
restriction optimizes the fast/feed cycle already conserved in our genome, and 
allows individuals to optimize its benefit. Overall, TRF downregulates 
mTOR/IGF-1 signaling while upregulating SIRT activity which are all associated 
with improved longevity. Individuals undergoing this regimen show minimization 
of anabolic processes, increased DNA repair, enhanced stress resistance, and 
improved autophagy and recycling of cellular components (29). Compliance with 
TRF does not seem to be an issue, and its benefits are similar to that of the 5:2 
diet. Given that neither have been proven harmful, there seems to be no strong 
preference for one or the other amongst researchers. Thus, both represent valid 
and useful tools to reduce metabolic dysregulation, chronic inflammation, and 





Dietary Restriction: What to Eat 
 In contrast to caloric restriction and intermittent fasting, another school of 
thought follows components of dietary restriction. This involves limiting the 
intake of protein and specific AA in order to target nutrient signaling pathways 
involved in longevity. Specifically, limiting the intake of serine, threonine, 
methionine, and protein has been shown to extend lifespan in yeast and animal 
models (79, 99, 78). Implicated in the benefits of dietary restriction is the AA 
regulator general control noderepressible 2 (GCN2) and the mTOR/IIS axis (79).  
 Serine and threonine came to light as pro-aging when it was discovered 
that cells become overly sensitized to oxidative stress with these AA in medium. 
Serine and threonine promote mTOR activation and ultimately inhibit stress 
resistance protein kinase Rim15 (20). In addition, AA scarcity activates GCN2 
which has been shown to promote longevity as well. Methionine restriction is also 
involved in this pathway, in particular it reduces IGF-1 signaling, described 
earlier to promote longevity as well. Common diets which naturally limit intake 
of these AA include vegan diets, plant proteins, and moderate intake of beans, 
legumes, and soy (78). Therefore, not only controlling when you eat, but what 
you eat could optimize the function of prolongevity functions, and allow the body 





 It is a common belief that regular exercise is beneficial to overall health, 
both physical and mental. Applied physiologist and leader in longevity-based 
medicine Peter Attia has even challenged his followers to take on the 
‘Centenarian Olympics’; a regimen of targeted workouts designed to conserve 
functionality into later years. Kettlebell swings to mimic lifting up a child, squats 
to conserve the ability to sit and stand independently, and cardio exercise for 
cardiac health are just a few examples (33). However, the true benefit of these 
exercises is not rooted in muscle memory or motor control, but the regimen’s 
effect on energy metabolism, stress management,  and overall muscle mass which 
translates improved stamina, reduction in DNA damage, and resistance to frailty 
(36). RCTs have shown that a combination of aerobic exercise and resistance 
training improve diet-induced weight loss, VO2max, cancer-suppression, 
inflammatory suppression,  and scores in modified physical performance test in 
frail older adults (2,87).  
 Particular exercise regimens which are considered to promote longevity 
include high intensity interval training (HIIT) and progressive resistance training. 
HIIT involves exercise-induced increase in heart rate to more than 90% 
interrupted by periods of rest. A systematic review of over 2000 studies noted 
improvements in CVD biomarkers in children and adolescents, and concluded 
that HIIT is an effective time-effective intervention to promote health (31). 
Progressive resistance training involves 10 weighted exercises for  10-15 
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repetitions at moderate intensity (2). Benefits include muscular synthesis, 
improved physical function, and overall amelioration of frailty (40). By 
modifying exercise depending on current ability, and encouraging consistency, 
physicians can empower their patients to take their health into their own hands in 

































 There is no ‘one-size-fits-all’ method to promote longevity in individuals. 
If the age of lightning fast-genomics and big data have shown us anything is that 
we are each infinitely unique in our own right. Personalized medicine is on a 
constant rise to being the status quo of healthcare, acknowledging that our 
uniqueness demands unique care. That being said, there are some things you can 
do today to try and secure a healthier and more independent future.  
 It is now clear that aging is not something to fear or ostracize. With older 
age come wisdom, experience, and life lessons critical to future generations. 
Therefore, there is much to gain by empowering the elderly to continue to 
contribute to society and maintain independence. There is no rule that says aging 
must be accompanied by suffering. Studies of numerous aging theories have 
shown that the way we age is something that can be modulated, delayed, and 
therefore improved. Key proteins players such as the sirtuins and mTOR are being 
described and targeted in new studies all the time. Genetic manipulation is 
another exciting and new field which may yet prove to contribute to longevity 
therapeutics as well. Perhaps chronic diseases such as CVD and dementia may 
become less prevalent in the future as the shift from symptom-based care to 
preventative medicine continues to take hold in hospitals and medical schools 
alike.  
The easiest things to implement into our routine in order to promote 
longevity are those things which we can personally control; the way we diet and 
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exercise. The evidence in support of intermittent fasting with little negative 
effects beyond feelings of hunger is only growing. Just by restricting when you 
eat, and how much you eat in a day can jump start your journey to becoming an 
active grandparent. Simple cardiovascular exercise for twenty minutes three times 
a week is low-cost in the sense of time and money but unlocks incredible benefits 
for cardiac and metabolic health. Overall, the idea of ‘staying active’ seems to be 
key. The body follows a “use-it-or-lose-it” mantra, and so stimulating your 
metabolism by caloric and dietary restriction, undertaking consistent cardio and 
resistance exercise, and challenging one’s cognition by continuing to pursue new 
accolades seem to all contribute to improved state of well-being in later years. 
Pharmaceuticals and supplements, for the time being, should be something to be 
wary of. Longitudinal studies for efficacy and safety are still underway for 
compounds such as STACs, metformin, and Rapamycin and although time is 
always of the essence with aging, jumping the gun on these interventions before 
they are proven is a risk.  
I encourage you, the reader, not only to challenge yourself to age better 
but those around you. In life, it may seem that past a certain point whatever 
damage has been done is not worth attempting to resolve, and whatever bad habits 
we formed are far beyond repair. I urge you to look past this stark mentality, and 
believe in the resiliency of not only the body but the human spirit. Start with small 
steps. Stop eating between 10pm and 10am by skipping breakfast, push that 10am 
mark 1 hour a day until you are only eating after 2pm and just like that you begin 
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to reap the benefit of fasting. Walk two miles every other day until eventually you 
begin to run through them. Surround yourself with those who uphold a positive 
mental attitude and inspire you to better yourself. Just like that, you begin to take 
control of not only your current health, but what your future may look like. For all 
you know, those two miles may one day translate into 26.2 as you cross the finish 
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